A PHASE I OPEN LABEL STUDY OF THE SAFETY AND TOLERABILITY OF ELOTUZUMAB (BMS-901608) ADMINISTERED IN COMBINATION WITH EITHER LIRILUMAB (BMS-986015) OR URELUMAB (BMS-663513) IN SUBJECTS WITH MULTIPLE MYELOMA: